Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29161134 | 1.00 | SLC18A3 (0.33) | SLC18A3CA1CA2CA4HSD17B10 | |
| SCHEMBL26708757 | 0.81 | MAPT (0.37) | SLC18A3CA1CA2CA4HSD17B10 | |
| SCHEMBL4613757 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL21757863 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL7733797 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL8161261 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL13767450 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL3038819 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL712232 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 | |
| SCHEMBL838630 | 0.74 | CA1 (0.46) | SLC18A3CA1CA2CA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113736056-B | Compositions, methods of making the same, and materials made therefrom | 财团法人工业技术研究院 | 2023-02-28 | — | — | CN | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | SLC18A3 1539/4885CA1 180/4885CA2 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.